TBUFF Stock UPDATES Tribute Pharmaceuticals Canada Inc. (TBUFF)

New Post Public Reply Private Reply Replies (0) Message Board

Sep 10, 2014 at 5:26 PM

Tribute Pharmaceuticals Canada Inc. (TBUFF) 0.5075 $TBUFF

Tribute Pharmaceuticals Reports Solid Second Quarter 2014 Results
Marketwire - Mon Aug 11, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) ("Tribute" or the "Company"

, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and U.S., today announced financial results for its quarter ending June 30, 2014. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).

Tribute Pharmaceuticals to Host Second Quarter 2014 Earnings Conference Call and Webcast Live on Monday, August 11, 2014
ACCESSWIRE - Fri Aug 08, 3:26PM CDT
MILTON, ONTARIO / ACCESSWIRE / August 8, 2014 / Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) will host a conference call and live webcast to discuss the results of the second quarter 2014, to be held Monday, August 11, 2014 at 11:00 AM Eastern Time.

Tribute Pharmaceuticals Schedules Second Quarter 2014 Financial Results Conference Call
Marketwire - Wed Aug 06, 11:17AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF) (TSX VENTURE: TRX) ("Tribute" or the "Company"

, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that it will host a conference call on Monday, August 11, 2014 at 11 AM EDT to review and discuss the Company's results for its second quarter ending June 30, 2014.

Tribute Pharmaceuticals Begins Trading on the OTCQX Marketplace
Marketwire - Tue Aug 05, 6:32AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQX: TBUFF)(TSX VENTURE: TRX) ("Tribute" or the "Company"

, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced that its common shares will begin trading today on the OTCQX(R) marketplace under the symbol "TBUFF". Tribute's common shares will also continue to trade on the TSX Venture Exchange under the symbol "TRX".

Tribute Pharmaceuticals to Present at the Bloom Burton & Co. Annual Healthcare Conference
Marketwire - Mon Jun 16, 7:03AM CDT
Tribute Pharmaceuticals Canada Inc. ("Tribute" or "the Company"

(TSX VENTURE: TRX) (OTCQB: TBUFF), a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada and the U.S., today announced today that its President and Chief Executive Officer, Rob Harris, will present an update on the Company and its corporate activities, at the Bloom Burton & Co. ("Bloom Burton"

Annual Healthcare Investor Conference, to be held on Wednesday, June 18 at the Toronto Board of Trade.

Tribute Pharmaceuticals Reports Full Year 2013 Results and Lays the Groundwork for Future Growth
Marketwire - Mon Mar 31, 6:03AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or the "Company"

, a Canadian specialty pharmaceutical company engaged in the acquisition, licensing, development and promotion of healthcare products in Canada and the United States, today announced financial results for its fiscal year ending December 31, 2013. In this press release, all dollar amounts are expressed in Canadian currency (unless otherwise noted) and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).

CAMBIA(R) Update From Tribute Pharmaceuticals
Marketwire Canada - Fri Dec 20, 7:00AM CST
Tribute Pharmaceuticals Canada Inc. (OTCQB:TBUFF) (OTCBB:TBUFF) (PINKSHEETS:TBUFF) ("Tribute" or the "Company"

, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today commented on the recent acquisition of CAMBIA(R) (diclofenac potassium for oral solution) by Depomed, Inc. (NASDAQ

EPO). Depomed, Inc. ("Depomed"

announced earlier this week that it had acquired the United States and Canadian rights to CAMBIA(R) (diclofenac potassium for oral solution) from Nautilus Neurosciences, Inc. ("Nautilus"

of Bedminster, NJ. For a complete copy of Depomed's recent press release please visit www.depomed.com.

OTC Daily Alert Stock Watch - Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)
WorldStockWire - Sat Sep 07, 12:00AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com

Tribute Pharmaceuticals Announces Double Digit Growth in Second Quarter 2013
Marketwire - Fri Aug 09, 8:52AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company"

, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for its fiscal 2013 second quarter ending June 30, 2013. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).

Tribute Pharmaceuticals Announces Double Digit Growth in First Quarter 2013
Marketwire - Tue May 14, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (formerly Stellar Pharmaceuticals Inc.) (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company"

, a specialty pharmaceutical company with a primary focus on the acquisition, licensing, development and promotion of healthcare products in Canada, today announced financial results for its fiscal 2013 first quarter ending March 31, 2013. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).

Tribute Pharmaceuticals Reports 2012 Year-End Results with Strong Revenue Growth
Marketwire - Thu Mar 21, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF) ("Tribute" or "the Company"

, a Canadian specialty pharmaceutical company, today announced financial results for the year ended December 31, 2012. In this press release, all dollar amounts are expressed in Canadian currency - unless otherwise noted - and results are reported in accordance with United States generally accepted accounting principles (U.S. GAAP).

Tribute Pharmaceuticals Expands Previously Announced Financing to Raise $4.6 Million
Marketwire - Fri Mar 15, 6:31AM CDT
Tribute Pharmaceuticals Canada Inc. (OTCQB: TBUFF)(OTCBB: TBUFF)(PINKSHEETS: TBUFF) ("Tribute" or "the Company"

, a Canadian specialty pharmaceutical company, today announced it has closed the second and final tranche of its privately placement of securities for aggregate gross proceeds of an additional US$1.2 million with private investors who are unaffiliated with the Company. These funds were raised in addition to a first tranche of securities sold for aggregate gross proceeds of US$3.4 million which included participation from, among others, the Company's Chief Executive Officer, Chief Financial Officer and certain members of its Board of Directors (see press release dated March 4, 2013). The three tranches together total approximately US$4.6 million.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Inovonics Duress Card Enhances Safety for K-12 and Beyond

A New Dawn for Safety in Schools and More It's about time we talk about something more substantial than just beefing up security cameras or tightening door locks. Real-world problems require nimble solutions, and that's where Status Solutions steps in with the Inovonics Duress Card. It's not just another gadget; it's a lightweight, wrist-mounted lifeline designed to say,...

FC2 Condom Educates NYC on Health and Wellness

Union Square Becomes a Hub of Interactivity The heart of NYC pulsed with purpose as FC2 Female Condom set up shop in Union Square, using the iconic location as a stage for a different kind of celebration. Clear Future, the manufacturer behind FC2, marked Global Female Condom Day with an event unlike any other. It wasn't just about the product—it was a call to educate...

TWP & Commbi Unveil Exclusive Pony Clog Collaboration

A Fusion of Fashion and Functionality Walk down the streets of New York or hustle your way through an airport without worrying about your footwear weighing you down. That's the promise coming from the fresh alliance between TWP and Commbi with their new Pony Clog Collaboration. A blend of high fashion and everyday utility, these clogs aren't just keeping up with the...

Alcott HR's Sales Strategy Gets a Boost with New Hire

Alcott HR Ramps Up Sales Firepower Now here's something fresh from the world of human resources outsourcing—Alcott HR has grabbed a new ace for their sales team. Eldin Radoncic is the name you'll want to remember, folks, because he's diving headfirst into the Director of Sales seat at this IRS Certified and ESAC Accredited player based out in good old Farmingdale, New...

BMAP Expands: Bridging Borders in Legal Advocacy

Breaking Down BMAP's Unique Approach Just when you thought you've seen it all, along comes LMU Loyola Law School swinging the doors wide open with their Binational Migrant Advocacy Project, or as we’re affectionately calling it, BMAP. It's a mouthful, sure, but ain't it something? This project isn't just another feather in academia's cap—it's a relentless counterpunch...

Paula's Choice Elevates Skincare Game with New Campaign

Strategy Meets Skincare: Paula's Choice in the Spotlight Catch this: Paula's Choice just dropped a moisturizer, but it ain't just lotion. No, the Pro-Collagen Peptide Plumping Intensive Moisturizer is here with a punch. And they've got Hannah Waddingham, of 'Ted Lasso' fame, fronting a campaign that screams confidence. Now, that's a way to announce your move at the...

Avive Partners with Cambridge Fire for Lifesaving Training

Tapping into the Pulse: Avive & Cambridge Fire in Action No fooling around here—Avive Solutions is linking arms with the Cambridge Fire Department to put the city on a faster track to becoming a lifesaver haven. They're rolling out a free CPR and AED training right in the Smith Campus Center, Harvard Square. It's the kind of thing you love to see—getting the community...

TGI Fridays Unveils New 3 For All Menu Options

Hedging Bets on New Dining Strategies Oh, the restaurant battlefield—where one day you're the toast of the town, and the next, you're hustling to keep those seats filled. TGI Fridays, a name as synonymous with casual eats as long as I’ve been in this game, is rolling the dice with a new offering dubbed '3 For All.' Doesn't sound like your average meal deal either....

Feeding Families Foundation Gains $121,500 for NYC Push

Holy smokes, here comes some good news in the nonprofit corners! Feeding Families Foundation just got a hefty $121,500 boost from the Association of Contracting Plumbers of the City of New York Inc. This ain't just some pocket change; it's a full-fledged lifeline that helps them keep on delivering meals to parents who are practically living at their kid’s hospital...

G-STAR & Wu-Tang Clan Unleash Denim Fusion

Denim and Old-School Beats: A Fresh Partnership Just when you think fashion collaborations have run their course, along comes something worth the buzz. This fall, G-STAR, the edgy Dutch denim frontrunner, and the legendary hip-hop collective of Wu-Tang Clan are shaking up the apparel scene, blending raw denim with raw rap. It's a multi-year collaboration that doesn't slap...